-

Stockholder Alert: Robbins LLP Informs Investors of the Gildan Activewear Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of former HanesBrands shareholders who acquired common shares of Gildan Activewear Inc. (NYSE/TSE: GIL) in connection with the December 2025 cash-and-stock exchange through which Gildan acquired HanesBrands. Gildan is a global manufacturer of everyday basic apparel, including activewear, underwear and sock products.

Robbins LLP is Investigating Allegations That Gildan Activewear Inc. Included False and Misleading Statements in Its Offering Documents in Support of Its HanesBrands Acquisition

Share

The lawsuit alleges that Gildan's Offering Materials contained materially false or misleading statements in that the Company artificially inflated its revenues through aggressive channel stuffing for years to advance short-term growth and pull forward future sales to meet revenue and earnings targets.

Investors who received Gildan securities in connection with the HanesBrands acquisition and suffered losses may have legal rights and should contact Robbins LLP for information about seeking appointment as lead plaintiff.

Why Was Gildan Sued?

According to the complaint, in December 2025, Gildan acquired and merged with HanesBrands. The complaint alleges that the Offering Materials contained false and misleading information because:

(1) even before the merger, Gildan was experiencing severe inventory loading by channel partners, with all the hallmarks of illicit channel stuffing and unsustainable customer demand;
(2) Gildan’s Days of Sales Outstanding had reached peak levels;
(3) intermediaries were already overloaded with inventory that would languish on shelves instead of being distributed; and
(4) the purported synergies and growth metrics emphasized in the Offering Materials were already unrealistic and unattainable.

Plaintiff alleges that this was happening while defendants pulled progressively more sales forward ahead of demand at quarter-ends across distribution channels.

What Happened to Gildan Stock?

The complaint contends that on June 16, 2026, investigative research firm Jehoshaphat Research published a 60-page report that described, among other things, how Gildan had been artificially inflating its revenues through aggressive “channel stuffing” for years to advance short-term growth and pull forward future sales in order to meet revenue and earnings targets. On this and other news, the price of Gildan common shares plummeted over 18%, or $11.63 per share, from $61.97 per share on June 15, 2026 to $50.34 per share on June 16, 2026.

Who May Be Eligible?

The proposed class includes investors who received Gildan Activewear Inc. (NYSE: GIL) securities in connection with Company's December 2025 cash-and-stock exchange acquisition of HanesBrands.

If you received Gildan securities in connection with the acquisition and suffered losses, you may have rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is an investor appointed by the court to represent the interests of the proposed class throughout the litigation.

Investors do not have to serve as lead plaintiff to potentially share in any future recovery if the lawsuit is successful.

If you are interested in seeking appointment as lead plaintiff, contact Robbins LLP for information.

Does it cost anything to participate?

No. Robbins LLP represents investors on a contingency fee basis. Investors never pay attorneys' fees or litigation expenses. If there is a recovery for shareholders, defendants pay attorneys' fees and expenses.

Contact Robbins LLP

Investors seeking additional information about the Gildan Activewear Inc. securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or call (800) 350-6003.

About Robbins LLP

Robbins LLP is a shareholder rights law firm representing investors in securities fraud and shareholder litigation. The firm has helped recover more than $1 billion for shareholders, secured significant corporate governance reforms at more than 400 Fortune 1000 companies, and has extensive experience prosecuting securities class actions nationwide.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Gildan Activewear Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:GIL

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom